Status:
COMPLETED
The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
Lead Sponsor:
Eisai Limited
Conditions:
Dementia With Parkinson's Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.
Eligibility Criteria
Inclusion
- Patients with an established diagnosis of PD and dementia, who fulfill all of the inclusion criteria and none of the exclusion criteria listed below, will be eligible for enrolment into this study.
- Best efforts must be made on clinical grounds to exclude patients with DLB and AD. The key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of PD.
Exclusion
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00165815
Start Date
August 1 2002
End Date
July 1 2005
Last Update
May 10 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Allgemeines Krankenhaus Barmbeck
Hamburg, Hambug, Germany
2
Parkinson Klinik Wolfach
Wolfach, Wolfach, Germany
3
Belfast City Hospital
Belfast, Belfast, Ireland
4
Unit 20 Black Poo Technology Centerl
Blackpool, Blackpool, Ireland